Skip to main content

Table 2 Characteristics of trial participants by type of intervention

From: Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trials

 

Trials

All

ACT

AHT

APT

CEA

GL

HRT

Statins

Vitamins

P

All

  

N = 8

N = 8

N = 7

N = 3

N = 1

N = 2

N = 4

N = 2

 

Primary (%)

15

 

4 (36.7%)

6 (40.0%)

0

1 (6.7%)

1 (6.7%)

2 (13.3%)

1 (6.7%)

0

 

Secondary (%)

20

 

4 (20.0%)

2 (10.0%)

7 (35.0%)

2 (10.0%)

0

0

3 (15.0%)

2 (10.0%)

 

Baseline

 Number

35

254,223

54,713

81,058

39,714

5074

10,251

27,347

24,222

11,844

 

 Age

35

65.1 (30.5)

69.0 (11.7)

64.6 (51.9)

66.0 (9.6)

66.6 (8.2)

62.8 (6.6)

63.4 (7.2)

59.3 (8.1)

63.7 (12.1)

< 0.0001

 Sex, Female (%)

35

117,222 (46.1%)

21,063 (38.5%)

39,213 (48.4%)

14,697 (37.0%)

2711 (53.4%)

3952 (38.6%)

27,347 (100%)

3916 (16.2%)

4323 (36.5%)

< 0.0001†

Medical History (%)

 Diabetes

34

51,131 (20.1%)

7030 (12.9%)

17,143 (21.2%)

8897 (22.4%)

1135 (22.4%)

10,251 (100%)

1980 (7.2%)

1725 (7.1%)

2970 (25.3%)

< 0.0001‡

 Hypertension

32

153,427 (69.6%)

22,771 (67.0%)

76,550 (94.5%)

25,871 (65.2%)

3212 (63.3%)

–

8433 (34.0%)

8141 (33.6%)

8449 (72.0%)

< 0.0001

 Hyperlipidaemia

17

27,627 (29.8%)

96 (9.6%)

1019 (15.4%)

14,757 (37.3%)

1291 (37.8%)

–

3366 (13.7%)

4444 (40.2%)

2654 (41.7%)

< 0.0001

 IHD

12

27,850 (30.6%)

–

8813 (24.0%)

6724 (20.7%)

1970 (38.8%)

–

–

9014 (100%)

1329 (17.0%)

< 0.0001¥

 Stroke

28

21,645 (12.6%)

3403 (9.6%)

5375 (13.9%)

8707 (23.9%)

717 (21.0%)

630 (6.1%)

306 (1.1%)

369 (4.1%)

2138 (18.2%)

< 0.0001

 MI

25

22,069 (13.6%)

5073 (14.4%)

704 (2.1%)

2720 (7.7%)

640 (18.8%)

1590 (15.5%)

634 (2.3%)

10,708 (60.8%)

–

< 0.0001

 Smoking, Current

31

48,441 (20.9%)

7030 (21.0%)

17,515 (21.9%)

10,211 (25.8%)

1471 (29.0%)

1247 (12.2%)

2831 (10.5%)

3496 (14.4%)

4640 (39.5%)

< 0.0001

 Alcohol

12

27,897 (41.3%)

6373 (34.2%)

4754 (48.0%)

10,984 (40.5%)

561 (33.8%)

–

–

3098 (46.9%)

2127 (59.4%)

< 0.0001

 SBP

31

145.8 (23.1)

143.5 (27.1)

155.2 (19.8)

147.4 (20.2)

146.1 (19.3)

–

128.7 (17.6)

136.5 (18.8)

141.5 (20.9)

< 0.0001

 DBP

30

83.3 (12.0)

79.5 (12.8)

87.7 (11.1)

84.9 (11.7)

80.1 (10.0)

–

76.0 (9.2)

80.3 (10.4)

81.6 (12.1)

< 0.0001

 HR

14

73.1 (13.7)

75.1 (15.8)

77.5 (11.6)

73.2 (12.4)

73.1 (10.6)

–

–

67.8 (11.1)

–

< 0.0001

Secondary

 Qualifying event (%)

  Stroke

19

71,178 (66.4%)

19,779 (60.9%)

5632 (85.2%)

34,071 (85.8%)

1571 (46.0%)

–

–

–

10,125 (86.1%)

< 0.0001

  MI

19

25,528 (22.9%)

12,090 (37.2%)

–

–

–

–

–

1348 (76.3%)

–

< 0.0001

  TIA

19

9979 (9.3%)

347 (1.1%)

974 (14.7%)

5497 (13.8%)

1759 (51.6%)

–

–

–

1402 (11.9%)

< 0.0001

  OTR

18

91.2 (246.2)

3.2 (12.9)

418.0 (439.6)

31.0 (163.5)

47.9 (43.6)

–

–

507.4 (317.0)

60.2 (178.0)

< 0.0001

  1. ACT: anticoagulants; AHT: antihypertensives; APT: antiplatelets; CEA: carotid endarterectomy; DBP: diastolic blood pressure; GL: glucose lowering; HRT: hormone replacement therapy; IHD: ischaemic heart disease; MI: myocardial infarction; HR: heart rate; OTR: onset to randomisation; SBP: systolic blood pressure; TIA: transient ischaemic attack. Percentages (%) are out of the total number of participants with available data. Comparisons by Chi-Square test and ANOVA. †Excluding HRT group. ‡Excluding GL group. ¥Excluding Statins group